Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03937219 · ClinicalTrials.gov registry record · Phase 3
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
A Phase 3 study of Renal Cell Carcinoma, sponsored by Exelixis.
- Active
- Registry status
- Phase 3
- Development phase
- 855
- Enrollment target
- 20
- Study locations
NCT03937219 is a Phase 3 study of Renal Cell Carcinoma that is active but no longer recruiting, run by Exelixis. The registered enrollment target is 855 participants, above the 236-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (262% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT03937219, a Phase 3 study of Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Exelixis.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 855 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo. Approximately 840 eligible subjects with intermediate- or poor-risk advanced or metastatic RCC by IMDC criteria will be randomized in a 1:1 ratio at approximately 180 sites.
Conditions Studied
Interventions
- BIOLOGICAL Nivolumab
- DRUG Cabozantinib
- BIOLOGICAL Ipilimumab
- DRUG Cabozantinib-matched placebo
Study Locations (20)
Massachusetts
- Exelixis Clinical Site #7B - Boston
- Exelixis Clinical Site #7A - Boston
- Exelixis Clinical Site #7C - Boston
- Exelixis Clinical Site #6 - Burlington
New York
- Exelixis Clinical Site #159 - New York
- Exelixis Clinical Site #8 - New York
- Exelixis Clinical Site #19 - Syracuse
California
- Exelixis Clinical Site #116 - La Jolla
- Exelixis Clinical Site #166 - Orange
Florida
- Exelixis Clinical Site #29 - Boca Raton
- Exelixis Clinical Site #44 - Miami
Missouri
- Exelixis Clinical Site #24 - Kansas City
- Exelixis Clinical Site #4 - St Louis
Georgia
- Exelixis Clinical Site #3 - Atlanta
Illinois
- Exelixis Clinical Site #95 - Chicago
Maine
- Exelixis Clinical Site #69 - Scarborough
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 855 participants |
| Start Date | 2019-06-25 |
| Est. Completion | 2027-01-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03937219
The ClinicalTrials.gov registry entry for NCT03937219 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 855 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 236-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (262% higher). The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Nivolumab is the first listed.
NCT03937219 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Massachusetts, New York, California.
Frequently Asked Questions
What is clinical trial NCT03937219 about?
NCT03937219 is a clinical study titled "Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma". This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo. Approximately 840 eligible subjects with intermediate- or poor-risk advanced or metastatic RCC...
What is the current status of trial NCT03937219?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 855 participants. The study started on 2019-06-25. Estimated completion is 2027-01-31.
What conditions does trial NCT03937219 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma.
What interventions are being tested in trial NCT03937219?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Cabozantinib (DRUG), Ipilimumab (BIOLOGICAL), Cabozantinib-matched placebo (DRUG).
Who is sponsoring clinical trial NCT03937219?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03937219 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
RECRUITING · Phase 3
-
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.